New and highly sensitive ELISA technique for bioanalysis of bevacizumab

Published: 31/01/2018
New and highly sensitive ELISA technique for bioanalysis of bevacizumab
Source: WWW.EUREKALERT.ORG

Bevacizumab is an anti-growth factor vascular endothelial growth factor (VEGF) monoclonal antibody, it is the antiangiogenic agent at the most advanced stage of development in the treatment of NSCLC.This drug was selected because of its inter individual differences in clinical response, its therapeutic importance in the treatment of non-small cell lung cancer (NSCLC).

Read more
Related news
Comment
FACEBOOK